Sat.Aug 06, 2022 - Fri.Aug 12, 2022

A biotech startup gives Merck its next shot at Alzheimer’s

Bio Pharma Dive

Boston-based Cerevance uses samples of healthy and diseased human brain tissue to find new targets for central nervous system diseases

277
277

Our abysmal health care system

World of DTC Marketing

According to a 2021 study , 1.1 million deaths—including one in two of those under 65, thanks in large part to our abysmal health care system—”would have been averted if the U.S. had the mortality rates of other wealthy nations.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

The potential of virtual reality-based therapy for serious mental disorders

Pharmaceutical Technology

In June this year, it was announced that the US Food and Drug Administration (FDA) had granted UK-based OxfordVR a breakthrough device designation for its gameChangeVR treatment to deliver immersive cognitive behaviour therapy (CBT) to people suffering from schizophrenia and other mental illnesses.

Pharma Distribution: Carving New Ground

Pharmaceutical Commerce

Pharmaceutical distribution today is anything but monolithic.

94

2022 Research: The Rapid Rise of Ocean Freight Visibility

Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.

GentiBio partners with Bristol Myers as cell therapy for immune disease gains momentum

Bio Pharma Dive

The deal, worth as much as $2 billion, is the latest sign of industry interest in treatments that harness regulatory T cells, an approach behind several recent biotech startups

262
262

PhRMA lies to protect pharma profits

World of DTC Marketing

PhRMA is lying to protect its profits, and the lies have reached a new height as the Senate moved to adopt modest drug pricing negotiation measures in the Inflation Reduction Act.

More Trending

Regions On Rise: Life Sciences Across US

Pharmaceutical Commerce

Exploring the competitive and unique offerings in three of the US’s lower-cost economic development regions—and how success in these areas has been boosted by COVID.

Samantha Truex on biotech hiring, competing for funding and Upstream’s next steps

Bio Pharma Dive

The CEO recently led Upstream through a $200 million financing that will support development of an inflammatory disease drug. “We have what investors probably want at this time,” she told BioPharma Dive

Drugs 260

Why DTC isn’t, and is, marketing

World of DTC Marketing

CPG marketers are trying to maintain market share amid price increases and smaller product sizes, leading to a more significant jump in consumerism. But, in pharma marketing, the changes affect every product category.

Why aren’t digital pills taking off?

Pharmaceutical Technology

In 2017, the US Food and Drug Administration (FDA) broke ground by approving the first drug with an embedded biosensor to track its use. Proteus Health’s Abilify MyCite had an ingestible sensor that could track if a patient consumed the drug.

An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space

Speaker: Steve Goldstein, Sales Leader

Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.

Environmental Sustainability: An Imperative for the Life Sciences Sector

Pharmaceutical Commerce

Recognizing the sustainability issue is an important step, but the biopharmaceutical sector encompasses a complex set of networks and supply chains, so it is not straightforward to shift towards net zero across all operations.

Bristol Myers claims success in study testing earlier CAR-T use in multiple myeloma

Bio Pharma Dive

Abecma, which 2Seventy bio helps develop and sell, is currently approved for patients who have tried at least four other medicines for the blood cancer

What’s the most significant change in DTC?

World of DTC Marketing

Consumers have changed their shopping behavior due to the pandemic, and some of those changes are relevant for pharma marketers. The days of someone seeing an ad for a prescription drug and rushing to ask their doctor about it have replaced the quest for more information, usually online.

FDA grants Fast-Track status for Relmada’s major depressive disorder therapy

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted Fast-Track designation to Relmada Therapeutics’ REL-1017 as a single agent to treat major depressive disorder (MDD).

Mandatory COVID Vaccination Policy Template

The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.

After billions in legal costs, Johnson & Johnson plans to halt talc sales worldwide

Fierce Pharma

After billions in legal costs, Johnson & Johnson plans to halt talc sales worldwide. kdunleavy. Fri, 08/12/2022 - 09:14

Sales 114

Lilly criticizes Indiana abortion law, indicating it may look elsewhere to hire

Bio Pharma Dive

After Indiana’s governor signed a near-total abortion ban into law, the drugmaker said it will rethink future hiring in the state

246
246

Dismay as UK ‘drags its heels’ on AZ’s COVID antibody Evusheld

Pharma Phorum

Half a million people in the UK with conditions like blood cancer that prevents them being protected from COVID-19 vaccines are facing another winter shielding, because the government has shelved plans to offer treatment with AstraZeneca’s antibody therapy Evusheld.

Brexit fallout continues with batch testing concerns

Pharmaceutical Technology

More than a year and a half after the Brexit deal came into effect, the UK’s pharmaceutical industry is still trying to determine the likely impacts.

'Litany of false promises': Pharma bemoans drug pricing bill as patient advocates celebrate

Fierce Pharma

Litany of false promises': Pharma bemoans drug pricing bill as patient advocates celebrate. Mon, 08/08/2022 - 11:19

Drugs 105

Pfizer, Valneva take next step with Lyme disease shot, starting large trial

Bio Pharma Dive

The experimental vaccine is the most advanced candidate for the tick-borne disease and, if successful, would be the first to reach the market since withdrawal of GSK’s Lymerix

Digital health app linked to better outcomes in heart failure

Pharma Phorum

A study of a mobile health app used to support patients hospitalised with heart failure has concluded that it provided a modest improvement in quality-of-life scores, as well as better clinical outcomes.

US FDA approves Daiichi Sankyo-AstraZeneca’s Enhertu for lung cancer

Pharmaceutical Technology

The US Food and Drug Administration (FDA) has granted approval for Daiichi Sankyo and AstraZeneca ’s Enhertu (fam-trastuzumab deruxtecan-nxki) to treat unresectable or metastatic non-small cell lung cancer (NSCLC) in adults.

The fight is on: As US pricing reform advances through Congress, pharma gears up for a brawl

Fierce Pharma

The fight is on: As US pricing reform advances through Congress, pharma gears up for a brawl. fkansteiner. Thu, 08/11/2022 - 10:30

99

Gemini’s fall gives Disc a way around biotech’s IPO slump

Bio Pharma Dive

The biotech’s failed attempt to develop an eye disease drug has ended in a reverse merger that gives startup Disc Medicine a fast path to the public markets

Pfizer vaults into sickle cell market as GBT deal confirmed

Pharma Phorum

Pfizer’s reported interest in acquiring sickle cell disease specialist Global Blood Therapeutics (GBT) has been confirmed, with the $68.50-per-share deal valuing GBT at $5.4 billion.

AstraZeneca-Daiichi Sankyo’s Enhertu gets US FDA approval for breast cancer

Pharmaceutical Technology

AstraZeneca and Daiichi Sankyo ’s Enhertu (trastuzumab deruxtecan) has received expanded approval from the US Food and Drug Administration (FDA) to treat adults with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer.

HR 87

In warranty program, Pfizer will refund up to $50K for patients who discontinue use of rare disease drug

Fierce Pharma

In warranty program, Pfizer will refund up to $50K for patients who discontinue use of rare disease drug. kdunleavy. Tue, 08/09/2022 - 14:09

Drugs 97

GSK, Pfizer, Sanofi shares drop amid Zantac litigation concerns

Bio Pharma Dive

The companies could face liability related to their sales of the heartburn drug, which was withdrawn from market in the U.S. and other countries after impurities related to a likely carcinogen were detected

Sales 230

Cumulus’ gamified dry EEG system tops lab monitoring in trial

Pharma Phorum

An at-home electroencephalogram (EEG) headset used alongside game-like cognitive tasks developed by UK company Cumulus Neuroscience has been shown to be more effective than lab-based EEG monitoring in a clinical trial.

FDA makes moves to advance ALS research ahead of upcoming Amylyx AdCom

Pharmaceutical Technology

In the lead-up to a critical meeting that will influence the approval of a new drug for amyotrophic lateral sclerosis (ALS), the US Food and Drug Administration (FDA) has detailed its plans to advance rare neurodegenerative disease research.

Look out, Pfizer. With new approval, Bayer's Nubeqa is set to challenge Xtandi's prostate cancer crown

Fierce Pharma

Look out, Pfizer. With new approval, Bayer's Nubeqa is set to challenge Xtandi's prostate cancer crown. fkansteiner. Mon, 08/08/2022 - 10:03

94

Fresh off Enhertu success, AstraZeneca and Daiichi claim progress for next cancer drug

Bio Pharma Dive

A treatment that AstraZeneca acquired for up to $6 billion in 2020 is showing early promise as a combination agent in lung cancer, where it’s being tested alongside Merck & Co.’s ’s Keytruda

Drugs 231

GSK, Sanofi and Haleon ‘facing billions of dollars in Zantac liability’

Pharma Phorum

GSK, its consumer health spin-off Haleon and Sanofi could be on the hook for billions of dollars in potential damages over Zantac, a gastrointestinal drug pulled from the market in 2020 after it was linked to cases of cancer.

Health Canada accepts Paladin’s NDS for epilepsy-linked seizure therapy

Pharmaceutical Technology

Health Canada has accepted the New Drug Submission (NDS) of Endo International subsidiary Paladin Labs for cenobamate tablets as an adjunctive treatment to manage partial-onset seizures in adult epilepsy patients.